Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Patients undergoing long-term hemodialysis (HD) have a markedly reduced life expectancy, especially those on HD for more than 30 years. Coronavirus disease 2019 (COVID-19) increased the mortality in HD patients; however, little is known about the results in those on long-term HD. We aimed to observe the outcomes of patients receiving HD for more than 30 years after COVID-19 infection during the epidemic in two HD centers.
We retrospectively analyzed 8 patients from 2 HD centers who had been on HD for 30~35 years. They all suffered COVID-19 infection in 2022 and were followed up for 2 years. Demographic and clinical characteristics, laboratory parameters, and follow-up data were collected.
All 8 patients in the study were infected with COVID-19 (Omicron variant BA.2.2) during the outbreak, and they successfully recovered from the infection. They were aged from 52 to 72 years with an HD vintage of 30~35 years, including 3 males and 5 females. They all have a history of chronic glomerulonephritis and no comorbidities before initiating HD, receiving HD 3 times a week, and hemodiafiltration (HDF) once or twice per month.
The laboratory parameters included hemoglobin (88–118 g/L), serum albumin (27.7–39.7 g/L), prealbumin (106–283 g/L), calcium (1.88–2.55 mmol/L), phosphorus (0.76–1.99 mmol/L), creatinine (566–786 μmol/L) , and urea (12.52–31.46 mmol/L). All of them received adequate dialysis during long-term dialysis. The main clinical manifestations of COVID-19 infection are as follows: fatigue (8/8, 100%), fever (6/8, 75%), cough and expectoration (5/8, 62.5%), sore throat (4/8, 50%). One patient was admitted to the hospital due to a severe condition and received treatment with oral Paxlovid and continuous renal replacement therapy. Subsequently, due to dyspnea and hypotension, the patient was transferred to the kidney ICU, followed by a multidisciplinary collaborative treatment including circulatory monitoring and support, using specialized type of hemofilter (Oxiris) and psychological support therapy. The patient safely survived after a 17-day treatment.
Among the remaining 7 patients, 2 were on oral antiviral drugs, 3 were on oral antipyretics, and 2 did not take drugs. Their recovery time from COVID-19 varied from 1 week to 1 month. All 8 patients survived after a 24-month follow-up, with only 3 patients developing mild symptoms of long COVID (including cough, fatigue, and memory impairment) eventually.
Baseline health status, no comorbidities, young age at initiation of HD, and adequate dialysis may be crucial factors influencing the long-term survival of HD patients, especially when they were going through COVID-19 infection.
